Stay updated on Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded Revision: v3.4.2; removed the lapse-in-funding notice and the government operating status update, and removed Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check15 days agoChange DetectedAdded a site-wide notice about the lapse in government funding and open status, and updated the page revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check22 days agoChange DetectedShow glossary has been added, and several metadata labels were updated (Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0). Related topics and legacy labels (e.g., Melanoma, MedlinePlus Genetics, No FEAR Act data, Revision: v3.3.4) were removed.SummaryDifference0.4%

- Check29 days agoChange DetectedAdded Melanoma as a related topic and a MedlinePlus Genetics link as related topics on the study page.SummaryDifference0.2%

- Check36 days agoChange DetectedRevision: v3.3.4 was added; Melanoma, related topics: MedlinePlus Genetics, and Revision: v3.3.3 were removed from the page.SummaryDifference0.2%

- Check43 days agoChange DetectedMelanoma is added as the condition category and MedlinePlus Genetics is added as a related topic.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.